Home › Cancer (all types) › NCT07689864
Unified Network for Integrated Fluid Collection at Yale
RecruitingObservational study
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Histological or radiological evidence of a suspected or confirmed solid tumor or hematologic malignancy, OR an individual identified as high-risk for cancer (based on identified germline aberration in a cancer predisposition gene, hormonal or medical risk factors, and/or significant family history of malignancy). * Willing and able to provide informed consent and HIPAA authorization for participation in UNIFY. * If being co-consented for a separate primary research study, the participant must also fulfill the eligibility criteria for that primary research study. Where there is a discrepancy in eligibility criteria between UNIFY and the primary research study, the primary research study's criteria take precedence. Exclusion Criteria: * Inability to provide informed consent. * Any medical contraindication to peripheral venipuncture as judged by the treating physician or research team (e.g., severe coagulopathy or other contraindication to additional research blood draw).
About the study
UNIFY is a Yale-wide liquid biopsy master repository that prospectively collects Streck-tube blood, dried blood spots (and optional archival tissue) from Yale Cancer Center patients across all tumor types for current and future research.
Sponsor: Yale University · Participants: 2,500 · Started: Aug 25, 2026
Contact the study team
- Mitchell Elliott, MD · Phone: 475-375-7981
Official record on ClinicalTrials.gov — NCT07689864
Locations in the U.S.
| Connecticut | Smilow Cancer Hospital, New Haven |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.